RxDoctor Payments Data

Traci Radford, MD

Internal Medicine · Dallas, TXNPI 1194744466

Payments from drug & device makers

$14,324in general payments, 2019–2025

Across 939 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$941
  • Amarin Pharma, Inc.$925
  • Abbott$872
  • plus $7K from 48 others

What the payments were for

  • Consulting fees$8006%
  • Food & beverage$13,49794%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,324 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$113,541
Medicare patients
252
Services billed
1,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$70,104
TrulicityDulaglutide17$22,360
MounjaroTirzepatide16$22,339
VascepaIcosapent Ethyl11$11,552
JanuviaSitagliptin Phosphate11$10,299
SynthroidLevothyroxine Sodium109$8,503
ProgesteroneProgesterone, Micronized125$5,377
EvoxacCevimeline Hcl12$5,283
MyrbetriqMirabegron11$4,466
DexilantDexlansoprazole12$3,273
Liothyronine Sodium62$2,816
Estradiol20$2,794
Bupropion XlBupropion Hcl52$2,404
Estradiol (Twice Weekly)Estradiol35$2,211
BystolicNebivolol Hcl12$2,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,553$70,10469 claims
Lilly USA, LLCTrulicity, Mounjaro$941$44,69933 claims
MerckJanuvia$464$10,29911 claims
AbbVieSynthroid$1,964$8,503109 claims
Astellas Pharma US IncMyrbetriq$64$4,46611 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$412$3,27312 claims
Kowa Pharmaceuticals America, Inc.Bystolic$630$2,15612 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$492$2,083152 claims
PfizerDilantin$290$1,73112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →